At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 278 enrolled
Drug / intervention
MK-0954A +3 moredrug
Likely dose
MK-0954A 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®]
In Brief
A Phase 3 clinical trial evaluating MK-0954A, MK-954H, and 2 other interventions for Hypertension. Completed, enrolled 278 participants.
Detailed Summary
This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartMar 2011
Primary CompletionDec 2012
TodayJul 2026
First PostedMar 2, 2011
Enrollment StartMar 29, 2011
Primary CompletionDec 4, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.3 years ago
Interventions
MK-0954Adrug
Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
MK-954Hdrug
Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
Placebo to MK-0954Adrug
Placebo tablet to match MK-0954A, once daily
Placebo to MK-954Hdrug
Placebo tablet to match MK-954H, once daily